Caris to Offer Signal Genetics' Multiple Myeloma Profiling Test

Caris will exclusively offer Signal's Myeloma Prognostic Risk Signature, or MyPRS, test to community-based hematologists and medical oncologists across the US.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.